From cDNA microarrays to high-throughput proteomics. Implications in the search for preventive initiatives to slow the clinical progression of Alzheimer's disease dementia

Restorative Neurology and Neuroscience

Volumn 18, Issue 2-3, 2001, Pages 137-142

  Pasinetti, G M ^a   Ho, L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Biomarker; Dementia; Microarrays; Proteomics; SELDI; Synaptic function

Indexed keywords

BIOLOGICAL MARKER; BRAIN PROTEIN; COMPLEMENTARY DNA; GENE PRODUCT;

ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; CEREBROSPINAL FLUID ANALYSIS; DEMENTIA; DISEASE COURSE; DNA MICROARRAY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; METHODOLOGY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RISK ASSESSMENT; RISK FACTOR; SYNAPSE; TRANSCRIPTION REGULATION;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; DISEASE PROGRESSION; GENE EXPRESSION; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEOME;

EID: 0034775513     PISSN: 09226028     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. The use of SELDI protein-chip arrays to monitor production of Alzheimer's betaamyloid in transfected cells
2. Correlation of the clinical severity of Alzheimer's disease with an aberration in mitochondrial DNA (mtDNA)
3. Neuropeptide abnormalities in patients with early Alzheimer disease
4. The role of cholesterol in the biosynthesis of beta-amyloid
5. Proteomic strategies for biomarker identification: Progress and challenges
6. Synaptic vesicle phosphoproteins and regulation of synaptic function
7. Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease
8. Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease
9. Contribution of Lewy body inclusions to dementia in patients with and without Alzheimer disease neuropathological conditions
10. Synapsins as regulators of neurotransmitter release
11. Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for Alzheimer's disease assessed by DNA microarray technique
12. Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease
13. Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia
14. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease
15. Excitotoxicity but not beta-amyloid toxicity recapitulates changes in gene expression in the brain of cases at high risk for Alzheimer's disease dementia
16. Longitudinal studies of cognitive, functional and behavioural change in patients with Alzheimer's disease
17. The Clinical Dementia Rating (CDR): Current version and scoring rules
18. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline
19. The use of cDNA microarray in the search for molecular markers involved in the onset of Alzheimer's disease dementia
20. Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma
21. The origins of Alzheimer disease: A is for amyloid
22. The decline in synapses and cholinergic activity is asynchronous in Alzheimer's disease
23. Identification of a superimmunoglobulin gene family member overexpressed in benign prostatic hyperplasia